Zealand Pharma Leverages AI for Metabolic Disease Drug Development Ambitions
Zealand Pharma is leveraging artificial intelligence to enhance drug development for metabolic diseases, including severe obesity, with plans to advance over ten candidates to clinical development within five years. The company, backed by over $2.5 billion in funding, aims to build a highly valuable pipeline and has partnered with Roche and Boehringer Ingelheim on key projects. CEO Adam Steensberg announced these ambitions during the JP Morgan health conference, highlighting access to DCAI's supercomputer Gefion for innovation.
Theia Market Signal Identification - AI Assisted
Zealand Pharma aims to utilize artificial intelligence (AI) to enhance drug development for metabolic diseases, including severe obesity. CEO Adam Steensberg highlighted the company's 25 years of experience in discovering drug candidates during the JP Morgan health conference in San Francisco.
Zealand Pharma announced its strategy to build 'the world's most valuable pipeline' for metabolic diseases and recently secured access to DCAI's supercomputer Gefion to boost innovation. The company targets advancing over ten drug candidates into clinical development within the next five years, supported by a strong financial position of over $2.5 billion. Key projects include partnerships with Roche on petrelintide and Boehringer Ingelheim on survodutide, with significant Phase 2 and Phase 3 studies planned for 2026 and this year, respectively.
Comments